Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 11, 2012, Pages 938-943

  Fan, Ying ^a   Yang, Shusen ^a   Zhang, Xiukun ^a   Cao, Yang ^a   Huang, Yonglin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Diabetes mellitus; Ischaemia reperfusion injury; Ischaemic post conditioning; Isolated heart

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART PROTECTION; HEMODYNAMICS; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; STREPTOZOCIN DIABETES;

ANIMALS; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; HEART; HEMODYNAMICS; HEPTANOIC ACIDS; ISCHEMIC POSTCONDITIONING; MALE; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84868117729     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12014     Document Type: Article

References (28)

1. Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: Mechanisms and management. Ann. Intern. Med. 2003; 139: 824-34.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N. Engl. J. Med. 2007; 357: 1121-35.
3. Penna C, Mancardi D, Raimondo S, Geuna S, Pagliaro P. The paradigm of postconditioning to protect the heart. J. Cell Mol. Med. 2008; 12: 435-58.
4. Hausenloy DJ. Signaling pathways in ischaemic postconditioning. Thromb. Haemost. 2009; 101: 626-34.
5. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H1580-6.
6. Wagner C, Kloeting I, Strasser RH, Weinbrenner C. Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: Role of glycogen synthase kinase 3beta. J. Cardiovasc. Pharmacol. 2008; 52: 430-7.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
9. Adameova A, Harcarova A, Matejikova J et al. Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterol-lowering effects. Physiol. Res. 2009; 58: 449-54.
10. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 2003; 41: 508-15.
11. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996; 335: 1001-9.
12. Kocsis GF, Pipis J, Fekete V et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2008; 294: H2406-9.
13. Zhou YS, Gao Y, Guo XH, Li B, Wang S, Chi JM. Effects of timely insulin treatment on protection of beta cells in a rat model of type 2 diabetes mellitus. Chin. Med. J. 2004; 117: 1523-9.
14. Atar S, Ye Y, Lin Y et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H1960-8.
15. Liu YB, Yu B, Li SF et al. Mechanisms mediating the cardioprotective effects of rapamycin in ischaemia-reperfusion injury. Clin. Exp. Pharmacol. Physiol. 2011; 38: 77-83.
16. Szárszoi O, Malý J, Ostádal P et al. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol. Res. 2008; 57: 793-6.
17. Kant R, Diwan V, Jaggi AS, Singh N, Singh D. Remote renal preconditioning-induced cardioprotection: A key role of hypoxia inducible factor-prolyl 4-hydroxylases. Mol. Cell. Biochem. 2008; 312: 25-31.
18. Penumathsa SV, Thirunavukkarasu M, Koneru S et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell. Cardiol. 2007; 42: 508-16.
19. Di Filippo C, Marfella R, Cuzzocrea S et al. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 2005; 54: 803-10.
20. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr. Diabetes Rev. 2009; 5: 120-44.
21. Thibault H, Piot C, Staat P et al. Long-term benefit of postconditioning. Circulation 2008; 117: 1037-44.
22. Di Napoli P, Taccardi AA, Grilli A et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc. Res. 2005; 66: 462-71.
23. Cai W, Fang J, Chen ZY, Lin YL, Wu LM, Chen LL. Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 814-18.
24. Mullonkal CJ, Toledo-Pereyra LH. Akt in ischemia and reperfusion. J. Invest. Surg. 2007; 20: 195-203.
25. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J. Am. Coll. Cardiol. 2005; 45: 1287-91.
26. Chen Z, Peng IC, Sun W et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 2009; 104: 496-505.
27. Sun W, Lee TS, Zhu M et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-62.
28. Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: A key stress signaling pathway in the heart. Trends Cardiovasc. Med. 2005; 15: 110-18.